Congratulations, Jim Mulvahill!

James P. Mulvahill, CEO and Founder of Bennett Pharmaceuticals of America, has been nominated and recognized on the short-list for the 2023/2024 Denobi Awards for recognition acknowledging his accomplishment in founding a 503b pharmacy with an emphasis in producing necessary and affordable medicines for the dental industry. The Denobi Awards celebrate outstanding contributions to the dental industry from around the world.

The establishment of the 503b pharmacy by the FDA aimed to enhance patient safety in pharmaceutical compounding and address the scarcity of drugs on the shortage list. All products produced in a 503b undergo rigorous stability and microbial testing, ensuring that only the safest products reach doctors and dentists. Additionally, 503b facilities adherence to "cGMP" (current good manufacturing practices) which sets these pharmacies apart from conventional compounding pharmacies.

James P Mulvahill, in collaboration with Dr. Michael Smilanich, embarked on a mission to unite the realms of dentistry and the 503b pharmacy. Drawing on Dr. Smilanich's extensive 40 years of experience as a restorative dentist and Jim’s 20 years experience with the FDA, the team recognized the lack of effective topicals in the dental field and the potential benefits a 503b could bring to the industry. Thus, Orlicaine was invented.

 Jim’s initiative has significantly enhanced the production and accessibility of topical anesthetics within the dental field. The now patented topical anesthetic, Orlicaine, was crafted exclusively for mucosal tissue and produced in accordance with the 503b pharmacy guidelines. This innovative mission is bringing about a revolutionary change in the dental industry and elevating standards of practice in the dental field thanks to the work of James Mulvahill.

Try Orlicaine in your practice today: Orlicaine Topical